The PMPRB launched the second phase of consultations on its new Guidelines with the release of a Discussion Guide on June 26, 2024. You are invited to submit feedback on the topics set out in this Discussion Guide, via written submission, by September 11, 2024.
Tthe Patented Medicine Prices Review Board (PMPRB) has launched the second phase of its Guidelines consultations with the release of the Discussion Guide. The Discussion Guide provides seven topics for discussion with stakeholders. It also proposes to adopt certain directions for the future Guidelines, including: All patented medicine list prices will be reviewed on an approximately annual basis. … Read more
The Patented Medicine Prices Review Board published the eighth edition of its annual Meds Entry Watch report . The analysis finds that the number of new medicines launched in Canada is higher than the median for Organisation for Economic Co-operation and Development countries., Most new medicines come to market with high treatment costs, and specialty medicines such as biologic, … Read more
The Patented Medicine Prices Review Board (PMPRB) published its What We Learned Report, which summarizes the feedback received in the Policy Roundtable meetings it hosted in December 2023. The report, along with the written submissions received, will help inform the PMPRB’s next steps toward developing new Guidelines. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca. Health Minister … Read more
The latest edition of the Patented Medicine Prices Review Board CompassRx report shows that the 10 highest-cost drugs reimbursed by public drug plans in Canada were all rare disease treatments with annual treatment costs of over $250,000. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
The Patented Medicine Prices Review Board (PMPRB) invites stakeholders to comment on its Scoping paper for the consultations on the Board’s Guidelines. Stakeholders can voice their opinions at the Policy Roundtable as well as through written submissions. The deadline for registration to participate in the Roundtable is Nov. 24, 2023, and to submit written feedback is Dec. 20, 2023. A What We Heard … Read more
The Patented Medicine Prices Review Board will launch the first phase of consultations on its new Guidelines by inviting stakeholders to participate in a Policy Roundtable on Dec. 5 (English session) and Dec. 6 (French session). The intent of this phase is to foster a productive conversation, where all parties can voice their opinions and concerns. After … Read more
The Patented Medicine Prices Review Board (PMPRB) published the seventh edition of its annual Meds Entry Watch report. The analysis finds that the number of new medicines launched in Canada is higher than the median for Organisation for Economic Co-operation and Development countries but falls below the median of the eleven PMPRB comparators, all of which have lower … Read more
The latest edition of the Patented Medicine Prices Review Board Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2022, with cancer treatments representing nearly one third (30 per cent) of medicines in all phases of clinical trials. Treatments for infectious diseases held the second largest share of the … Read more
The Patented Medicine Prices Review Board (PMPRB) launched a new 60-day Notice and Comment period on June 20, encouraging stakeholders and interested members of the public to provide their input on new proposed Interim Guidance. The deadline for providing written submissions to the PMPRB is August 21, 2023. The full release is available online. Contact PMPRB.MediaCentre-CentreMedias.CEPMB@pmprb-cepmb.gc.ca.
